February 2026 QQ: DOACs

Our February 2026 Quick Question is a quiz that asks, “Which DOAC is a direct thrombin inhibitor?” Since 2010, DOACs have become our primary antithrombotic agents prescribed for prophylaxis or therapy. While more DOACs are on the horizon, the current anticoagulants directly inhibit either thrombin or FXa. Please make your selection in the right-hand column […]

Comments (0)

Quick Question Archive

Jan 26 2026

george

January 2026 QQ Summary: Fibrinolysis

Our January 2026 QQ was a quiz that asked, “What fibrinolytic enzyme digests fibrin?” Here’s how our 34 respondents scored: D-dimer: 0 Plasmin 28 (82%) PAI-1: 2 (6%) TAFI 0 TPA 4 (12%) Congratulations on your successful answers. Here is a summary of fibrinolysis (figure), paraphrased from Walenga JM, Krum KN. Normal Hemostasis. In Keohane EM, […]

Fibrinolysis

World Thrombosis Day Article: Renal Vein Thrombosis

Click here for a World Thrombosis Day article about Renal Vein Thrombosis. Introduction Renal vein thrombosis is a blood clot that occurs in the veins draining blood from the kidneys. A blood clot in the renal vein will impact kidney function because it slows the flow of blood from the kidney and can reduce the […]

Comments (0)

Anticoagulant Therapy

Jan 24 2026

george

Low-dose Emicizumab Efficacy

Obtain this clinical research article on low-dose emicizumab therapy from your medical library: Datta G, Verma SP, Sinha S, et al. Bridging the Gap: Efficacy of low-dose emicizumab in haemophilia A with or without inhibitors. Haemophilia. 2026. doi: 10.1111/hae.70211. PMID: 41549560. ABSTRACT Introduction Emicizumab has proven to be a turning point in the management of […]

Bleeding Disorders

A Historical Review: Two Decades of Hemostasis and Thrombosis genetics

Here is an open-access review of the genetics of hemostasis: Sabater-Lleal M, Thibord F, de Vries PS, et al. Historical review: more than two decades of understanding the genetic architecture of hemostasis and thrombosis. J Thromb Haemost. 2025:S1538-7836(25)00845-1. doi: 10.1016/j.jtha.2025.11.006. PMID: 41352609. Abstract From the beginning of the millennium and the development of genome-wide analyses, […]

Coagulation Factors

VWD In Women: Non-bleeding Health Issues

Click to read this open-access article that addresses the reproductive, medical, skeletal, psychosocial, and economic impact of VWD in women. Swan D, Sholzberg M, Bannow BS, Thachil J. Von Willebrand disease: more than just a bleeding disorder. Res Pract Thromb Haemost. 2025;10:103276. doi: 10.1016/j.rpth.2025.103276. PMID: 41536292; PMCID: PMC12796595. Abstract Von Willebrand disease (VWD) is the […]

Bleeding Disorders

Diagnostic Equity: PB Platelets in Myelofibrosis

This question appeared on the Diagnostic Equity website on 1-21-2026: “How well do peripheral blood platelet findings correlate with bone marrow fibrosis or megakaryocyte abnormalities in myelofibrosis, and when do lab results suggest a marrow reassessment might be useful?” Diagnostic Equity expert Ryan J. Tom, MS, MLS(ASCP)CM (DCLS Resident) offered this answer: Platelet findings can […]

Comments (0)

Platelet Function Testing

Jan 23 2026

george

Meta-analysis: D-dimer Safely Excludes Pulmonary Embolism in Cancer

Obtain this provocative article from your medical library: Vrotniakaite-Bajerciene K, Mallick R, Takada T, et al. Safety and efficiency of D-dimer testing in combination with clinical decision rules to exclude pulmonary embolism in patients with cancer: individual patient data meta-analysis. J Thromb Haemost. 2025:S1538-7836(25)00839-6. doi: 10.1016/j.jtha.2025.10.035. PMID: 41354153. Abstract Background: Failure rates of clinical decision […]

Thrombophilia

The Value of Offering DOAC Measurements

Obtain this article from your medical library: Swan D, Roberts L, Thachil J. In a nutshell: testing DOAC levels-when, why and what it means? Br J Haematol. 2026. doi: 10.1111/bjh.70313. PMID: 41482473. Abstract Plasma direct oral anticoagulant (DOAC) levels are not routinely required for the majority of patients; however, they may provide valuable information in […]

Comments (0)

Anticoagulant Therapy

Jan 19 2026

george

Retrospective Comparison of rVWF versus pdVWF During Hospitalization

Here is an open-access article describing the efficacy of vonicog alfa versus plasma-derived VWF: Horvais V, Ternisien C, Denis-Le-Sève J, et al. Vonicog alfa versus plasma-derived von Willebrand factor during hospitalization: results of an observational retrospective multicenter study. Semin Thromb Hemost. 2026. doi: 10.1055/a-2779-9176. PMID: 41529718. Abstract Available products for the treatment of von Willebrand […]

Comments (0)

Bleeding Disorders

All Posts

February 2026 QQ: DOACs

January 2026 QQ Summary: Fibrinolysis

World Thrombosis Day Article: Renal Vein Thrombosis

Low-dose Emicizumab Efficacy

A Historical Review: Two Decades of Hemostasis and Thrombosis genetics

VWD In Women: Non-bleeding Health Issues

Diagnostic Equity: PB Platelets in Myelofibrosis

Meta-analysis: D-dimer Safely Excludes Pulmonary Embolism in Cancer

The Value of Offering DOAC Measurements

Retrospective Comparison of rVWF versus pdVWF During Hospitalization

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question